- Cancer PHGKB -
Last Posted: Dec 12, 2019
- Cancer's epigenetic drugs: where are they in the cancer medicines?
Ghasemi Sorayya et al. The pharmacogenomics journal 2019 Dec
- Targeted deep-intronic sequencing in a cohort of unexplained cases of suspected Lynch syndrome.
Arnold Anke Marie et al. European journal of human genetics : EJHG 2019 Dec
- Tumor mutations are not alone in the plasma
K Naxoreva, Sci Trans Med, December 11, 2019
- Implementing universal cancer screening programs can help sustain genomic medicine programs
AK Rahm et al, Frontiers in Genetics, December 2019
- New AI-powered imaging technique IDs colorectal cancer with 100% accuracy
M Walter, AI in Health Care, December 10, 2019
- Appraising causal relationships of dietary, nutritional and physical-activity exposures with overall and aggressive prostate cancer: two-sample Mendelian-randomization study based on 79 148 prostate-cancer cases and 61 106 controls
N Kazmi et al, Int J Epi, December 5, 2019
- Current status of opioid addiction treatment and related preclinical research.
Kreek M J et al. Science advances 2019 Oct 5(10) eaax9140
- Biomarker-Driven Staging—Are We There Yet?
JAMA Network Open, December 6, 2019
- How Genetic Testing Saved One Woman's Life
K Kosko, Cure Magazine, December 6, 2019
- Population based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high grade serous ovarian cancer
MedRXIV, December 2019
- The Current Practice of Lynch Syndrome Diagnosis and Management in Italy: A Qualitative Assessment.
Tognetto Alessia et al. Public health genomics 2019 Dec 1-19
- As Use of Genomic Data Expands in Cancer Care, Patients Share Their Stories
NCI, December 3, 2019
- Progress Toward Precision Medicine in Frontline Treatment of Metastatic Renal Cell Carcinoma.
Singla Nirmish et al. JAMA oncology 2019 Dec
- CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer.
Wei Xiaoxia et al. Pharmacogenomics 2019 Nov
- 'We don't know for sure': discussion of uncertainty concerning multigene panel testing during initial cancer genetic consultations.
Medendorp Niki M et al. Familial cancer 2019 Nov
- CDC Information (107)
- NIH Information (235)
- CDC Genomics Publications (135)
- Human Genome Epidemiologic Studies (40368)
- GWAS Studies (583)
- Human Genomics Translation/Implementation Studies (4637)
- Genomic Tests Evidence Synthesis (515)
- Genomic Tests Guidelines (338)
- Tier-Classified Guidelines (179)
- Non-Genomics Precision Health (349)
- Pathogen Advanced Molecular Detection (173)
- State Public Health Genomics Programs (192)
- Reviews/Commentaries (3698)
- Tools/Methods (153)
- Ethical/Legal and Social Issues (ELSI) (149)
Quick Links to Other Resources
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.